Clinical Trials Browser

Phase 1 × Ovarian Neoplasms × Carboplatin × Clear all

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT06607185 2026-03-13

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Phase 1 Active not recruiting

750 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT01970722 2026-03-05

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Phase 1 Active not recruiting

40 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06400472 2026-01-14

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Phase 1 Recruiting

495 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

GyneRep

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

(VELA) Study of BLU-222 in Advanced Solid Tumors

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

IVY

OVMET

Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer

A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

ProGem2

Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers

A Study of SY-1365 in Adult Patients With Advanced Solid Tumors

Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin

Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer

Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer

Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

REVIVAL

Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian

Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer

Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer

Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors

Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer